Advances in Primary Biliary Cholangitis: Expert Insights on Emerging Data and Key Treatment Innovations - Episode 10
New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial
New studies reveal potential benefits of alfagimor in reducing fatigue and pruritus, highlighting its role in second-line therapy for patients.
This episode, titled “New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial” features panelists discussing highlighting recent data on elafibranor and how changes in fatigue/pruritus were largely independent from biomarker changes. Clinicians then discuss how this information may impact future treatment decisions.
Led by the moderator, the experts examine the following critical questions:
- Results announced from EASL and AASLD this year revealed that changes in fatigue and pruritus for patients on elafibranor from the phase III ELATIVE trial were largely independent from biomarker changes. Can you expand upon the clinical significance of these findings, especially for patients with severe symptomatic burden?
- Looking ahead, how can clinicians utilize this information to make targeted treatment decisions?
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon” panelists will continue their discussion on PBC and highlight investigational
